FDA orders new warnings on four drugs tied to fungal infection

09/4/2008 | Wall Street Journal (free content), The · NYTimes.com

The FDA called for stronger warnings on the labels of Johnson & Johnson's Remicade, Abbott Laboratories' Humira, Amgen and Wyeth's Enbrel and UCB's Cimzia to inform patients about the risk of developing histoplasmosis, a harmful fungal infection. The drugs, also known as tumor necrosis factor blockers, are approved in the U.S. for treating rheumatoid arthritis and Crohn's disease. The drugmakers are cooperating with the FDA for compliance, an agency official said.

View Full Article in:

Wall Street Journal (free content), The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI